With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.137076-54-1,2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid,as a common compound, the synthetic route is as follows.
(1)To a solution of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate tri-tert-butyl (24.8 mg), DMF (0.2 mL) and DIEA (17 muL) was added HBTU (17.0 mg) in DMF (100 muL), and then added to a solution of (L 7) (13.1 mg) in DMF (200 muL) and DIEA (10 muL) and stirred at room temperature for 1 hour. Water (200 muL) was added and purified by preparative HPLC to give (M 1) (12.3 mg).
137076-54-1 2-(4,7,10-Tris(2-(tert-butoxy)-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetic acid 11606627, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Patent; FUJIFILM Corporation; Fujifilm RI Pharma Co., Ltd.; Hirofumi, Fukunaga; Do En, Hiroyuki; Hino, Akihiro; Oshikiri, Shinobu; Chou, Rumpf; (131 pag.)JP2016/183151; (2016); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI